BIOMAT Database Logo BIOMAT Database Logo

Serum and Urine Monocyte Chemoattractant Protein-1 as A Markers for Lupus Nephritis. 2020

Mohamed A Abozaid, and Ghada H Ahmed, and Nabawia M Tawfik, and Sohair K Sayed, and Abeer M Ghandour, and Rasha A Madkour
Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt.

Lupus nephritis (LN) is a common major organ manifestation and main cause of morbidity and mortality of the disease. We aimed to determine the level of serum and urinary monocyte chemoattractant protein-1(sMCP-1 and uMCP-1) in systemic lupus erythematosus (SLE) patients with and without LN and analyze their association with different clinical and serologic parameters of disease activity. We enrolled 60 female patients with SLE (32 with LN and 28 without LN) and 20 controls.MCP-1 and anti-dsDNA were measured by ELISA. There was statistically significant increase in serum and urinary MCP-1 in all SLE patients (mean=711.59, 676.68 pg/ml respectively) as compared to the control group (mean= 635.70, 632.40 pg/ml respectively), P=0.034, 0.020 respectively. Among patients with LN there was statistically significant increase in sMCP-1 (mean=723.58) compared to the control group (P=0.038, and in uMCP-1 (mean=699.08) compared to patients without LN (mean=651.07) and control group (mean=632.40), P=0.007, 0.002 respectively. Urinary, but not serum MCP-1, positively correlated with 24 hour proteinuria, anti-dsDNA, renal SLEDAI ,biopsy activity index (r=0.362, P=0.004; r=0.303, P=0.019; r= 0.267, P=0.039; r=0.353, P=0.047 respectively) and negatively correlated with serum albumin (r=-0.329, P=0.010).There was statistically significant increase in uMCP-1 and anti-dsDNA in patients with poor response compared to patients with good response to immunosuppressant therapy (P= 0.025; P=0.034 respectively). In conclusion, uMCP-1 is associated with LN and disease activity and may be used as a useful tool for diagnosis and follow up.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008181 Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982). Glomerulonephritis, Lupus,Lupus Glomerulonephritis,Nephritis, Lupus,Glomerulonephritides, Lupus,Lupus Glomerulonephritides,Lupus Nephritides,Nephritides, Lupus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D018932 Chemokine CCL2 A chemokine that is a chemoattractant for MONOCYTES and may also cause cellular activation of specific functions related to host defense. It is produced by LEUKOCYTES of both monocyte and lymphocyte lineage and by FIBROBLASTS during tissue injury. It has specificity for CCR2 RECEPTORS. Monocyte Chemoattractant Protein-1,Monocyte Chemotactic Protein-1,CCL2 Chemokine,Chemokine (C-C Motif) Ligand 2,Chemokines CCL2,Monocyte Chemotactic and Activating Factor,CCL2, Chemokine,CCL2, Chemokines,Chemoattractant Protein-1, Monocyte,Chemokine, CCL2,Chemotactic Protein-1, Monocyte,Monocyte Chemoattractant Protein 1,Monocyte Chemotactic Protein 1

Related Publications

Mohamed A Abozaid, and Ghada H Ahmed, and Nabawia M Tawfik, and Sohair K Sayed, and Abeer M Ghandour, and Rasha A Madkour
Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis.
October 2009, The Journal of rheumatology,
Mohamed A Abozaid, and Ghada H Ahmed, and Nabawia M Tawfik, and Sohair K Sayed, and Abeer M Ghandour, and Rasha A Madkour
[Expression of monocyte chemoattractant protein-1 and lupus nephritis].
August 2005, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
Mohamed A Abozaid, and Ghada H Ahmed, and Nabawia M Tawfik, and Sohair K Sayed, and Abeer M Ghandour, and Rasha A Madkour
Urinary monocyte chemoattractant protein-1 as a biomarker of lupus nephritis activity in children.
January 2015, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,
Mohamed A Abozaid, and Ghada H Ahmed, and Nabawia M Tawfik, and Sohair K Sayed, and Abeer M Ghandour, and Rasha A Madkour
Urine Monocyte Chemoattractant Protein-1 and Lupus Nephritis Disease Activity: Preliminary Report of a Prospective Longitudinal Study.
January 2015, Autoimmune diseases,
Mohamed A Abozaid, and Ghada H Ahmed, and Nabawia M Tawfik, and Sohair K Sayed, and Abeer M Ghandour, and Rasha A Madkour
Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis.
November 2010, Pediatric nephrology (Berlin, Germany),
Mohamed A Abozaid, and Ghada H Ahmed, and Nabawia M Tawfik, and Sohair K Sayed, and Abeer M Ghandour, and Rasha A Madkour
Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis.
December 1995, Laboratory investigation; a journal of technical methods and pathology,
Mohamed A Abozaid, and Ghada H Ahmed, and Nabawia M Tawfik, and Sohair K Sayed, and Abeer M Ghandour, and Rasha A Madkour
Longitudinal assessment of monocyte chemoattractant protein-1 in lupus nephritis as a biomarker of disease activity.
November 2016, Clinical rheumatology,
Mohamed A Abozaid, and Ghada H Ahmed, and Nabawia M Tawfik, and Sohair K Sayed, and Abeer M Ghandour, and Rasha A Madkour
Urine Monocyte Chemoattractant Protein-1(UMCP-1) as a Biomarker of Renal Involvement in Systemic Lupus Erythematosus.
November 2012, Iranian journal of basic medical sciences,
Mohamed A Abozaid, and Ghada H Ahmed, and Nabawia M Tawfik, and Sohair K Sayed, and Abeer M Ghandour, and Rasha A Madkour
Urinary neutrophil gelatinase-associated lipocalin and monocyte chemoattractant protein 1 as biomarkers for lupus nephritis in Colombian SLE patients.
April 2018, Lupus,
Mohamed A Abozaid, and Ghada H Ahmed, and Nabawia M Tawfik, and Sohair K Sayed, and Abeer M Ghandour, and Rasha A Madkour
Association of monocyte chemoattractant protein 1 (MCP-1) gene polymorphism with lupus nephritis in Egyptian patients.
October 2015, Human immunology,
Copied contents to your clipboard!